A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 992-1001

  Schlecht Louf, Géraldine ^a   Mangeney, Marianne ^a   El Garch, Hanane ^b   Lacombe, Valérie ^b   Poulet, Hervé ^b   Heidmann, Thierry ^a  

^a Institut Gustave Roussy   (France)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANARYPOXVIRUS VECTOR; FELINE LEUKEMIA VIRUS VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; POXVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANARYPOX VIRUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; ENVELOPE GENE; EXPERIMENTAL CAT; EXPRESSION VECTOR; FELINE LEUKEMIA; FELINE LEUKEMIA VIRUS; GENE MUTATION; GENE TARGETING; GROUP SPECIFIC ANTIGEN GENE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRO GENE; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROVOCATION TEST; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

ANIMALS; CANARYPOX VIRUS; CATS; FEMALE; GENE PRODUCTS, ENV; GENETIC VECTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; INTERLEUKIN-10; LEUKEMIA VIRUS, FELINE; LEUKEMIA, FELINE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTATION, MISSENSE; PROTEIN STRUCTURE, TERTIARY; RETROVIRIDAE PROTEINS, ONCOGENIC; VIRAL VACCINES;

EID: 84891690236     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02234-13     Document Type: Article

References (51)

1. Addie DD, Dennis JM, Toth S, Callanan JJ, Reid S, Jarrett O. 2000. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet. Rec. 146:419-424. http://dx.doi.org/10.1136/vr.146.15.419.
2. Meli ML, Cattori V, Martínez F, López G, Vargas A, Palomares F, López-Bao JV, Hofmann-Lehmann R, Lutz H. 2010. Feline leukemia virus infection: a threat for the survival of the critically endangered Iberian lynx (Lynx pardinus). Vet. Immunol. Immunopathol. 134:61-67. http://dx.doi.org/10.1016/j.vetimm.2009.10.010.
3. Cunningham MW, Brown MA, Shindle DB, Terrell SP, Hayes KA, Ferree BC, McBride RT, Blankenship EL, Jansen D, Citino SB, Roelke ME, Kiltie RA, Troyer JL, O'Brien SJ. 2008. Epizootiology and management of feline leukemia virus in the Florida puma. J. Wildl. Dis. 44:537-552. http://dx.doi.org/10.7589/0090-3558-44.3.537.
4. Nolen RS. 2004. Feline leukemia virus threatens endangered panthers. J. Am. Vet. Med. Assoc. 224:1721-1722.
5. Lee IT, Levy JK, Gorman SP, Crawford PC, Slater MR. 2002. Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats. J. Am. Vet. Med. Assoc. 220:620-622. http://dx.doi.org/10.2460/javma.2002.220.620.
6. Bandecchi P, Dell'Omodarme M, Magi M, Palamidessi A, Prati MC. 2006. Feline leukaemia virus (FeLV) and feline immunodeficiency virus infections in cats in the Pisa district of Tuscany, and attempts to control FeLV infection in a colony of domestic cats by vaccination. Vet. Rec. 158:555-557. http://dx.doi.org/10.1136/vr.158.16.555.
7. Little S. 2011. A review of feline leukemia virus and feline immunodeficiency virus seroprevalence in cats in Canada. Vet. Immunol. Immunopathol. 143:243-245. http://dx.doi.org/10.1016/j.vetimm.2011.06.018.
8. Hofmann-Lehmann R, Huder JB, Gruber S, Boretti F, Sigrist B, Lutz H. 2001. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats. J. Gen. Virol. 82:1589-1596.
9. Torres AN, Mathiason CK, Hoover EA. 2005. Re-examination of feline leukemia virus: host relationships using real-time PCR. Virology 332:272-283. http://dx.doi.org/10.1016/j.virol.2004.10.050.
10. Tandon R, Cattori V, Gomes-Keller MA, Meli ML, Golder MC, Lutz H, Hofmann-Lehmann R. 2005. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J. Virol. Methods 130:124-132. http://dx.doi.org/10.1016/j.jviromet.2005.06.017.
11. Cattori V, Pepin AC, Tandon R, Riond B, Meli ML, Willi B, Lutz H, Hofmann-Lehmann R. 2008. Real-time PCR investigation of feline leukemia virus proviral and viral RNA loads in leukocyte subsets. Vet. Immunol. Immunopathol. 123:124-128. http://dx.doi.org/10.1016/j.vetimm.2008.01.018.
12. Hofmann-Lehmann R, Cattori V, Tandon R, Boretti FS, Meli ML, Riond B, Pepin AC, Willi B, Ossent P, Lutz H. 2007. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine 25:5531-5539. http://dx.doi.org/10.1016/j.vaccine.2006.12.022.
13. Suntz M, Failing K, Hecht W, Schwartz D, Reinacher M. 2010. High prevalence of non-productive FeLV infection in necropsied cats and significant association with pathological findings. Vet. Immunol. Immunopathol. 136:71-80. http://dx.doi.org/10.1016/j.vetimm.2010.02.014.
14. Major A, Cattori V, Boenzli E, Riond B, Ossent P, Meli ML, Hofmann-Lehmann R, Lutz H. 2010. Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection. Vet. Res. 41:17. http://dx.doi.org/10.1051/vetres/2009065.
15. Sparkes AH. 1997. Feline leukaemia virus: a review of immunity and vaccination. J. Small Anim. Pract. 38:187-194. http://dx.doi.org/10.1111/j.1748-5827.1997.tb03339.x.
16. Poulet H, Brunet S, Boularand C, Guiot AL, Leroy V, Tartaglia J, Minke J, Audonnet JC, Desmettre P. 2003. Efficacy of a canarypox virusvectored vaccine against feline leukaemia. Vet. Rec. 153:141-145. http://dx.doi.org/10.1136/vr.153.5.141.
17. Hofmann-Lehmann R, Tandon R, Boretti FS, Meli ML, Willi B, Cattori V, Gomes-Keller MA, Ossent P, Golder MC, Flynn JN, Lutz H. 2006. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 24:1087-1094. http://dx.doi.org/10.1016/j.vaccine.2005.09.010.
18. Hoover EA, Mullins JI. 1991. Feline leukemia virus infection and diseases. J. Am. Vet. Med. Assoc. 199:1287-1297.
19. Flynn JN, Hanlon L, Jarrett O. 2000. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology 101:120-125. http://dx.doi.org/10.1046/j.1365-2567.2000.00089.x.
20. Flynn JN, Dunham SP, Watson V, Jarrett O. 2002. Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. J. Virol. 76:2306-2315. http://dx.doi.org/10.1128/jvi.76.5.2306-2315.2002.
21. Robert-Tissot C, Rüegger VL, Cattori V, Meli ML, Riond B, Gomes-Keller MA, Vögtlin A, Wittig B, Juhls C, Hofmann-Lehmann R, Lutz H. 2011. The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation. Vet. Immunol. Immunopathol. 143:269-281. http://dx.doi.org/10.1016/j.vetimm.2011.06.005.
22. Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. 1993. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J. Virol. 67:2370-2375.
23. O'Donovan LH, McMonagle EL, Taylor S, Bain D, Pacitti AM, Golder MC, McDonald M, Hanlon L, Onions DE, Argyle DJ, Jarrett O, Nicolson L. 2005. A vector expressing feline mature IL-18 fused to IL-1beta antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus. Vaccine 23:3814-3823. http://dx.doi.org/10.1016/j.vaccine.2005.02.026.
24. Torres AN, O'Halloran KP, Larson LJ, Schultz RD, Hoover EA. 2010. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet. Immunol. Immunopathol. 134:122-131. http://dx.doi.org/10.1016/j.vetimm.2009.10.017.
25. El Garch H, Richard S, Piras F, Leard T, Poulet H, Andreoni C, Juillard V. 2006. Feline leukemia virus (FeLV)-specific IFNγ+ T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine. Int. J. Appl. Res. Vet. Med. 4:100-108.
26. Haraguchi S, Good RA, Cianciolo GJ, Engelman RW, Day NK. 1997. Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. J. Leukoc. Biol. 61:654-666.
27. Copelan EA, Rinehart JJ, Lewis M, Mathes L, Olsen R, Sagone A. 1983. The mechanism of retrovirus suppression of human T cell proliferation in vitro. J. Immunol. 131:2017-2020.
28. Orosz CG, Zinn NE, Olsen RG, Mathes LE. 1985. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines. J. Immunol. 134:3396-3403.
29. Orosz CG, Zinn NE, Olsen RG, Mathes LE. 1985. Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphokine secretion. J. Immunol. 135:583-590.
30. Lafrado LJ, Lewis MG, Mathes LE, Olsen RG. 1987. Suppression of in vitro neutrophil function by feline leukaemia virus (FeLV) and purified FeLV-p15E. J. Gen. Virol. 68:507-513. http://dx.doi.org/10.1099/0022-1317-68-2-507.
31. Mathes LE, Olsen RG, Hebebrand LC, Hoover EA, Schaller JP, Adams PW, Nichols WS. 1979. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus. Cancer Res. 39:950-955.
32. Mangeney M, Heidmann T. 1998. Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc. Natl. Acad. Sci. U. S. A. 95:14920-14925. http://dx.doi.org/10.1073/pnas.95.25.14920.
33. Blaise S, Mangeney M, Heidmann T. 2001. The envelope of Mason-Pfizer monkey virus has immunosuppressive properties. J. Gen. Virol. 82:1597-1600.
34. Mangeney M, de Parseval N, Thomas G, Heidmann T. 2001. The full-length envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties. J. Gen. Virol. 82:2515-2518.
35. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, Letzelter C, Richaud A, Ducos B, Heidmann T. 2007. Placental syncytins: genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc. Natl. Acad. Sci. U. S. A. 104:20534-20539. http://dx.doi.org/10.1073/pnas.0707873105.
36. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, Bouallaga I, Heidmann T. 2010. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc. Natl. Acad. Sci. U. S. A. 107:3782-3787. http://dx.doi.org/10.1073/pnas.0913122107.
37. Stewart MA, Warnock M, Wheeler A, Wilkie N, Mullins JI, Onions DE, Neil JC. 1986. Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J. Virol. 58:825-834.
38. Blaise S, de Parseval N, Bénit L, Heidmann T. 2003. Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution. Proc. Natl. Acad. Sci. U. S. A. 100:13013-13018. http://dx.doi.org/10.1073/pnas.2132646100.
39. Fass D, Harrison SC, Kim PS. 1996. Retrovirus envelope domain at 1.7 angstrom resolution. Nat. Struct. Biol. 3:465-469. http://dx.doi.org/10.1038/nsb0596-465.
40. Kobe B, Center RJ, Kemp BE, Poumbourios P. 1999. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl. Acad. Sci. U. S. A. 96:4319-4324. http://dx.doi.org/10.1073/pnas.96.8.4319.
41. Renard M, Varela PF, Letzelter C, Duquerroy S, Rey FA, Heidmann T. 2005. Crystal structure of a pivotal domain of human syncytin-2, a 40 million years old endogenous retrovirus fusogenic envelope gene captured by primates. J. Mol. Biol. 352:1029-1034. http://dx.doi.org/10.1016/j.jmb.2005.07.058.
42. Kane M, Golovkina T. 2010. Common threads in persistent viral infections. J. Virol. 84:4116-4123. http://dx.doi.org/10.1128/JVI.01905-09.
43. Sun K, Torres L, Metzger DW. 2010. A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection. J. Virol. 84:5007-5014. http://dx.doi.org/10.1128/JVI.02408-09.
44. Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, French RA, Study Group ATAHC. 2011. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J. Viral. Hepat. 18:549-561. http://dx.doi.org/10.1111/j.1365-2893.2010.01335.x.
45. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12:1301-1309. http://dx.doi.org/10.1038/nm1492.
46. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG. 2006. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203:2461-2472. http://dx.doi.org/10.1084/jem.20061462.
47. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. 2008. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 223:114-131. http://dx.doi.org/10.1111/j.1600-065X.2008.00635.x.
48. O'Garra A, Vieira P. 2007. T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7:425-428. http://dx.doi.org/10.1038/nri2097.
49. Ignatius R, Marovich M, Mehlhop E, Villamide L, Mahnke K, Cox WI, Isdell F, Frankel SS, Mascola JR, Steinman RM, Pope M. 2000. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J. Virol. 74:11329-11338. http://dx.doi.org/10.1128/JVI.74.23.11329-11338.2000.
50. Ryan EJ, Harenberg A, Burdin N. 2007. The canarypox-virus vaccine vector ALVAC triggers the release of IFN-gamma by natural killer (NK) cells enhancing Th1 polarization. Vaccine 25:3380-3390. http://dx.doi.org/10.1016/j.vaccine.2006.12.048.
51. Harenberg A, Guillaume F, Ryan EJ, Burdin N, Spada F. 2008. Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. Vaccine 26:5004-5013. http://dx.doi.org/10.1016/j.vaccine.2008.07.050.